Steroid showdown: can prednisolone save lungs in rare fibrotic disease?
NCT ID NCT07210008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the steroid prednisolone can slow the decline in lung function for people with fibrotic hypersensitivity pneumonitis, a lung disease caused by inhaling certain substances. About 120 adults with mild to moderate lung impairment will receive either prednisolone or a placebo for 6 months. The main goal is to see if the treatment helps preserve breathing capacity better than a dummy pill.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROTIC HYPERSENSITIVITY PNEUMONITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to slow lung scarring in hypersensitivity pneumonitis
- Can a buddy system ease the burden of a rare lung disease?
- Lung disease study probes hidden environmental triggers
- Could weak legs be making it hard to breathe? new study investigates
- Can a breath test predict lung scarring? new study seeks answers
- Blood test may predict lung decline in rare disease